Video

Impact of Anti-EGFR Therapies on HER2-Positive Metastatic Colorectal Cancer (HER2+ mCRC): A Systematic Literature Review and Meta-Analysis of Clinical Outcomes

Author(s):

Tanios Bekaii-Saab, MD
Related Videos
BDTX-1535 – A MasterKey EGFR Inhibitor Targeting Classical, Non-Classical, and the C797S Resistance Mutation To Address The Evolved Landscape Of EGFR Mutant NSCLC
BTK Inhibitors in CLL : Second Generation Drugs and Beyond
Amin Nassar, MD
Pashtoon Murtaza Kasi, MD, MS
Katrina S. Pedersen, MD, MS, associate professor, John T. Milliken Department of Medicine, Division of Oncology, Medical Oncology program leader, cofounder, Young Onset Colorectal Cancer Program, Washington University School of Medicine in St. Louis, Siteman Cancer Center
A panel of 4 experts on colorectal cancer
Heinz-Josef Lenz, MD, FACP
A panel of 4 experts on colorectal cancer
Related Content
Here is your guide to important regulatory approvals made by the FDA in May 2024.
May 31st 2024

OncLive’s May Roundup of Key FDA Approvals in Oncology

John H. Strickler, MD
February 6th 2023

FDA Approval Insights: Tucatinib and Trastuzumab in HER2+ mCRC

FDA
May 24th 2024

FDA Advisory Committee Recommends Approval of Shield Blood Test for CRC Detection in Average-Risk Adults

Research Reflections: Subbiah Reviews Striking ASCO 2022 Data Across Oncology
August 1st 2022

Research Reflections: Subbiah Reviews Striking ASCO 2022 Data Across Oncology

Benjamin A. Weinberg, MD
May 10th 2024

Advances in MRD Testing Help Guide Optimal Colorectal Cancer Therapy

FDA
May 7th 2024

FDA Approves Noninvasive Stool RNA Screening Test for CRC